Current Report Filing (8-k)
March 23 2018 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 23, 2018
PLx Pharma Inc.
|
(Exact name of registrant as specified in its charter)
|
|
|
|
Delaware
|
001-36351
|
46-4995704
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
8285 El Rio Street, Ste. 130, Houston, Texas
|
77054
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s Telephone Number, Including
Area Code:
(713) 842-1249
|
(Former Name or Former Address, If Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On March 23, 2018, PLx
Pharma Inc. (the “
Company
”) issued a press release announcing its financial results for its fourth quarter
and full fiscal year ended December 31, 2017. The Company’s press release is attached hereto as Exhibit 99.1 and the information
set forth therein is incorporated herein by reference and constitutes a part of this report.
The information furnished
by the Company pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, (the “
Exchange Act
”) or otherwise subject to the
liability of that section, and shall not be deemed to be incorporated by reference into any Company filing under the Securities
Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PLX PHARMA INC.
|
|
|
|
|
|
|
|
Dated: March 23, 2018
|
By:
|
/s/ Natasha Giordano
|
|
|
|
Name:
|
Natasha Giordano
|
|
|
|
Title:
|
President and Chief Executive Officer
|
|
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Apr 2024 to May 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From May 2023 to May 2024